Ostroumova O D, Garelik I A
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Kardiologiia. 2016 Dec;56(12):20-26.
to compare effects of fixed-dose combinations of antihypertensive drugs that block renin-angiotensin-aldosterone system (RAAS) with hydrochlorothiazide (HCT) on parameters of ambulatory blood pressure monitoring (ABPM).
Patients (n=50; 25 women, 25 men aged 40-75 years) with stage II essential hypertension who received no antihypertensive therapy for 12 weeks were randomized to receive once daily fixed-dose combinations of either valsartan/HCT (Val/HCT - group I) or quinapril/HCT (Quin/HCT - groupII) in starting doses of 80/12.5 or 10/12.5 mg, respectively. If target BP (<140 and 90 mm Hg) was not achieved after 2 weeks, doses were increased to 160/12.5 and 20/12.5 mg, respectively. Patients in whom target BP was not achieved after another 2 weeks were excluded from the study. Follow - up after achieving target BP was 12 weeks.
Both combinations significantly (p<0.001) reduced office systolic and diastolic BP (SBP and DBP), however, BP decrease in group I was significantly (p<0.01) greater (-42.0+/-2,7 /-22.2+/-1.2 mm Hg) than in group II (-26,4+/-2,1/-6.6+/-0.4 mm Hg). Significant reduction of day- and night-time BP (p<0.001) observed in both groups was also more pronounced (p<0.01) in group I. In both groups we recorded significant (p<0.01) decreases of BP variability and morning BP rise. Variability of DBP at night (-3.3+/-0.2 mm Hg), magnitude and speed of morning DBP surge (-20.9+/-0.3 mm Hg and -3.4+/-0.2 mm Hg/hour, respectively) in group I decreased significantly (p<0.05) greater compared with same parameters in group II (-2.5+/-0.2 mm Hg, -17.7+/-0.3 mm Hg, -2.6+/-0.2 mm Hg/hour, respectively).
Fixed-dose combinations of RAAS blockers and HCT provided reliable reduction of BP, BP variability, morning BP rise, and high percentage of achievement of target BP. Val/HCT combination was more effective in terms of reducing SBP, DBP and pulse BP levels at routine measurement, and day- and night-time SBP and DBP, night-time DBP variability, and rate of morning DBP rise.
比较阻断肾素 - 血管紧张素 - 醛固酮系统(RAAS)的抗高血压药物与氢氯噻嗪(HCT)的固定剂量组合对动态血压监测(ABPM)参数的影响。
50例(25例女性,25例年龄40 - 75岁男性)II期原发性高血压患者,12周内未接受抗高血压治疗,随机分为每日一次接受缬沙坦/HCT(缬沙坦/HCT - I组)或喹那普利/HCT(喹那普利/HCT - II组)的固定剂量组合,起始剂量分别为80/12.5或10/12.5毫克。如果2周后未达到目标血压(<140和90毫米汞柱),剂量分别增加至160/12.5和20/12.5毫克。再过2周仍未达到目标血压的患者被排除在研究之外。达到目标血压后的随访时间为12周。
两种组合均显著(p<0.001)降低诊室收缩压和舒张压(SBP和DBP),然而,I组的血压下降幅度显著(p<0.01)大于II组(-42.0±2.7 /-22.2±1.2毫米汞柱比-26.4±2.1/-6.6±0.4毫米汞柱)。两组均观察到日间和夜间血压显著降低(p<0.001),I组更为明显(p<0.01)。两组均记录到血压变异性和晨起血压升高显著(p<0.01)降低。与II组相同参数(分别为-2.5±0.2毫米汞柱、-17.7±0.3毫米汞柱、-2.6±0.2毫米汞柱/小时)相比,I组夜间舒张压变异性(-3.3±0.2毫米汞柱)、晨起舒张压升高幅度和速度(分别为-20.9±0.3毫米汞柱和-3.4±0.2毫米汞柱/小时)显著(p<0.05)降低更多。
RAAS阻滞剂与HCT的固定剂量组合能可靠降低血压、血压变异性、晨起血压升高,并使目标血压达标率高。缬沙坦/HCT组合在常规测量时降低SBP、DBP和脉压水平,以及日间和夜间SBP和DBP、夜间DBP变异性和晨起DBP升高率方面更有效。